GAS6 and ovarian carcinoma: The growth arrest-specific protein 6 (GAS6) – AXL tyrosine kinase (AXL) interaction, for example, which are both associated with poor outcome, have already been evaluated in clinical trials in ovarian cancer by inhibiting their interaction (67).